Ameritas Investment Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,585
| Closed | -$4.78K | – | 3302 |
|
|
2023
Q1 | $4.78K | Hold |
2,585
| – | – | ﹤0.01% | 2870 |
|
|
2022
Q4 | $2.92K | Hold |
2,585
| – | – | ﹤0.01% | 2987 |
|
|
2022
Q3 | $6K | Hold |
2,585
| – | – | ﹤0.01% | 2914 |
|
|
2022
Q2 | $7K | Hold |
2,585
| – | – | ﹤0.01% | 2928 |
|
|
2022
Q1 | $18K | Hold |
2,585
| – | – | ﹤0.01% | 2612 |
|
|
2021
Q4 | $22K | Hold |
2,585
| – | – | ﹤0.01% | 2612 |
|
|
2021
Q3 | $19K | Hold |
2,585
| – | – | ﹤0.01% | 2743 |
|
|
2021
Q2 | $18K | Buy |
2,585
+1,352
| +110% | +$11.2K | ﹤0.01% | 2801 |
|
|
2021
Q1 | $13K | Hold |
1,233
| – | – | ﹤0.01% | 2758 |
|
|
2020
Q4 | $9K | Hold |
1,233
| – | – | ﹤0.01% | 2855 |
|
|
2020
Q3 | $10K | Hold |
1,233
| – | – | ﹤0.01% | 2737 |
|
|
2020
Q2 | $9K | Hold |
1,233
| – | – | ﹤0.01% | 2795 |
|
|
2020
Q1 | $6K | Hold |
1,233
| – | – | ﹤0.01% | 2784 |
|
|
2019
Q4 | $11K | Hold |
1,233
| – | – | ﹤0.01% | 2719 |
|
|
2019
Q3 | $4K | Hold |
1,233
| – | – | ﹤0.01% | 2967 |
|
|
2019
Q2 | $6K | Hold |
1,233
| – | – | ﹤0.01% | 2934 |
|
|
2019
Q1 | $8K | Hold |
1,233
| – | – | ﹤0.01% | 2779 |
|
|
2018
Q4 | $4K | Hold |
1,233
| – | – | ﹤0.01% | 2897 |
|
|
2018
Q3 | $8K | Hold |
1,233
| – | – | ﹤0.01% | 2901 |
|
|
2018
Q2 | $9K | Hold |
1,233
| – | – | ﹤0.01% | 2872 |
|
|
2018
Q1 | $28K | Hold |
1,233
| – | – | ﹤0.01% | 2250 |
|
|
2017
Q4 | $16K | Buy |
1,233
+613
| +99% | +$9.01K | ﹤0.01% | 2564 |
|
|
2017
Q3 | $10K | Hold |
620
| – | – | ﹤0.01% | 2787 |
|
|
2017
Q2 | $9K | Hold |
620
| – | – | ﹤0.01% | 2849 |
|
|
2017
Q1 | $14K | Buy |
+620
| New | +$13.1K | ﹤0.01% | 2580 |
|
Other funds holding JNCE
Ameritas Investment Partners's JNCE Position: Q2 2023 in Review
Ameritas Investment Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 2,585 shares — an estimated $4.78K sold.
Ameritas Investment Partners first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $28K in Q1 2018. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Ameritas Investment Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Ameritas Investment Partners sold 2,585 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.78K.
- Ameritas Investment Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Ameritas Investment Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $28K in Q1 2018.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.